Side-by-side · Research reference
MT-1vsSemaglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED9/51 cited
BFDA-ApprovedFlagship15/53 cited
MT-1
α-MSH Analogue · FDA-Approved
SQ Implant · 60-Day Release
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
MT-1
Semaglutide
Primary target
Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Pathway
α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
Downstream effect
Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Feedback intact?
Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production
Glucose-dependent insulin release preserves physiological feedback
Origin
Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Antibody development
—
—
02Dosage Protocols
Parameter
MT-1
Semaglutide
Standard dose
16 mg subcutaneous implant
FDA-approved formulation (Scenesse).
—
Frequency
Every 60 days
Sustained release implant — no daily administration required.
Once weekly, same day each week
Evidence basis
Phase 3 RCT / FDA-approved orphan drug
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Indication
Erythropoietic protoporphyria (EPP)
Narrow FDA approval — not licensed for cosmetic tanning.
—
Duration
Seasonal use (spring–autumn typical)
Aligned with peak UV exposure months.
Indefinite for chronic indication
Discontinuation results in weight regain.
Route
Subcutaneous implant — upper arm or abdomen
—
Stability
Norleucine/D-Phe substitutions enhance peptidase resistance
Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).
—
Standard dose (weight, Wegovy)
—
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
Titration schedule
—
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
Reconstitution
—
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
Timing
—
Any time of day, with or without food
04Side Effects & Safety
Parameter
MT-1
Semaglutide
Nausea
Common (>10%) — mild, transient
—
Implant site reaction
Erythema, bruising, tenderness at insertion site
—
Hyperpigmentation
Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010Habbema 2017
Expected melanogenic response — complicates pigmented lesion surveillance.
—
Melanocytic changes
Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017
Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.
—
Headache
Occasional (MC1R-independent melanocortin effects)
—
Photosensitivity (paradoxical)
Rare phototoxic reactions despite melanin increase
—
Contamination risk (unregulated)
Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010Habbema 2017
Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.
—
Injection site reaction
—
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
Hypoglycemia
—
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Heart rate
—
Modest ↑ resting HR (~2-4 bpm)
Absolute Contraindications
MT-1
- ·Hypersensitivity to afamelanotide or excipients
- ·Hepatic impairment (no safety data)
- ·Renal impairment (no safety data)
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Relative Contraindications
MT-1
- ·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
- ·Pregnancy/lactation (insufficient data)
- ·Photosensitive dermatoses (other than EPP)
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
05Administration Protocol
Parameter
MT-1
Semaglutide
1. Implant insertion
Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
2. Site care
Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
3. Release kinetics
Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.
Once weekly, same day. Day can be changed if ≥2 days separate doses.
4. Repeat dosing
New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
5. Monitoring
Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
06Stack Synergy
MT-1
— no documented stacks
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)